Phase II Study of High-Dose [131I]Metaiodobenzylguanidine Therapy for Patients With Metastatic Pheochromocytoma and Paraganglioma
Open accessThe DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
Purpose: To evaluate the safety and efficacy of high-dose [131 I]metaiodobenzylguanidine ([131 I]MIBG) in the treatment of malignant pheochromocytoma (PHEO) and paraganglioma (PGL). Methods: Fifty patients with metastatic PHEO or PGL, age 10 to 64 years, were treated with [131 I]MIBG doses ranging from 492 to 1,160 mCi (median, 12 mCi/kg). Cumulative [131 I]MIBG administered ranged from 492 to 3,191 mCi. Autologous hematopoietic stem cells were collected and cryopreserved before treatment with [131 I]MIBG greater than 12 mCi/kg or with a total dose greater than 500 mCi. Sixty-nine [131 I]MIBG infusions were given, which included infusions to 35 patients treated once and infusions to 15 patients who received two or three treatments. Response was evaluated by [123 I]MIBG scans, computed tomography/magnetic resonance imaging, urinary catecholamines/metanephrines, and chromogranin A. Results: The overall complete response (CR) plus partial response (PR) rate in 49 evaluable patients was 22%. Additionally, 35% of patients achieved a CR or PR in at least one measure of response without progressive disease, and 8% of patients maintained stable disease for greater than 12 months. Thirty-five percent of patients experienced progressive disease within 1 year after therapy. The estimated 5-year overall survival rate was 64%. Toxicities included grades 3 to 4 neutropenia (87%) and thrombocytopenia (83%). Grades 3 to 4 nonhematologic toxicity included acute respiratory distress syndrome (n = 2), bronchiolitis obliterans organizing pneumonia (n = 2), pulmonary embolism (n = 1), fever with neutropenia (n = 7), acute hypertension (n = 10), infection (n = 2), myelodysplastic syndrome (n = 2), and hypogonadism (n = 4). Conclusion: Although serious toxicity may occur, the survival and response rates achieved with high-dose [131 I]MIBG suggest its utility in the management of selected patients with metastatic PHEO and PGL.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Averbuch, S. D., Steakley, C. S., Young, R. C., Gelmann, E. P., Goldstein, D. S., Stull, R., & Keiser, H. R. (1988) · Annals of Internal Medicine · doi:10.7326/0003-4819-109-4-267 · Cited by 427 · cited 2×
“In 14 patients with metastatic pheochromocytoma, this therapy produced CR/PR in 57%.(9) More recently, results from a 22-year follow-up of 18 patients treated with CVD chemotherapy showed a CR rate of 11% and a PR rate of 44%, but 5-year survival of patients was less than 50%.”
BackgroundLoh, K.-C., Fitzgerald, P. A., Matthay, K. K., Yeo, P. P. B., & Price, D. C. (1997) · Journal of Endocrinological Investigation · doi:10.1007/bf03348026 · Cited by 278 · cited 1×
“the hormonal response rate was 45%.(8) However, the criteria for responses were not presented.”
BackgroundSelf-citationHuang, H., Abraham, J., Hung, E., Averbuch, S. D., Merino, M. J., Steinberg, S. M., Pacák, K., & Fojo, T. (2008) · Cancer · doi:10.1002/cncr.23812 · Cited by 276
Matthay, K. K., Tan, J. C., Villablanca, J. G., Yanik, G. A., Veatch, J., Franc, B., Twomey, E., Horn, B., Reynolds, C. P., Groshen, S., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.6400 · Cited by 197 · cited 1×
“[(131)I]MIBG was infused intravenously in a lead-shielded room over 2 hours with intravenous hydration, a Foley catheter for bladder protection, and potassium iodide and potassium perchlorate for thyroid protection.(6) Granisetron and lorazepam were given for radiation-induced nausea.”
MethodSelf-citationRationale and Evidence for Sunitinib in the Treatment of Malignant Paraganglioma/Pheochromocytoma
Joshua, A. M., Ezzat, S., Asa, S. L., Evans, A. J., Broom, R. J., Freeman, M., & Knox, J. J. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-1836 · Cited by 166 · cited 6×
“MDS was previously reported in three of 95 children treated at UCSF with [131I]MIBG for neuroblastoma, and a literature review revealed an additional three patients.18 www.jco.org © 2009 by American Society of Clinical Oncology 4167 In summary, high-dose [131I]MIBG produced objective responses in patients with metasta…”
BackgroundInfluentialMatthay, K. K., Panina, C., Huberty, J. P., Price, D. C., Glidden, D. V., Tang, H. R., Hawkins, R. A., Veatch, J., & Hasegawa, B. H. (2001) · PubMed · Cited by 161
Self-citationHigh‐dose 131I‐metaiodobenzylguanidine therapy for 12 patients with malignant pheochromocytoma
Rose, B., Matthay, K. K., Price, D., Huberty, J., Klencke, B., Norton, J. A., & Fitzgerald, P. A. (2003) · Cancer · doi:10.1002/cncr.11518 · Cited by 158 · cited 3×
“[(123)I]MIBG scans were evaluated on the basis of the general impression of the interpreting radiologist, as follows: CR was described as the disappearance of all lesions; PR, a decrease in the number and/or intensity of lesions; SD, no discernible change; and PD, the appearance of new lesions.(4) Radiologists were no…”
BackgroundMethodSelf-citationPheochromocytoma: an update on genetics and management
Karagiannis, A. I., Mikhailidis, D. P., Athyros, V. G., & Harsoulis, F. (2007) · Endocrine Related Cancer · doi:10.1677/erc-07-0142 · Cited by 150 · cited 1×
“SDHB mutations are autosomal dominant and are characterized by the development of paragangliomas with significant metastatic potential.(12) In this study, patients with known SDHB mutations were significantly more likely to achieve CR/PR.”
BackgroundFITZGERALD, P. A., Goldsby, R. E., Huberty, J. P., Price, D. C., Hawkins, R. A., Veatch, J., Cruz, F. S. D., Jahan, T. M., LINKER, C. A., Damon, L. E., et al. (2006) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1353.050 · Cited by 127
Self-citation
Cited by
Radiopharmaceutical therapy in cancer: clinical advances and challenges
Sgouros, G., Bodei, L., McDevitt, M. R., & Nedrow, J. R. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0073-9 · Cited by 963
Fassnacht, M., Assie, G., Baudin, E., Eisenhofer, G., de la Fouchardiere, C., Haak, H. R., de Krijger, R., Porpiglia, F., Terzolo, M., & Berruti, A. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.08.2099 · Cited by 436
Personalized Management of Pheochromocytoma and Paraganglioma
Nölting, S., Bechmann, N., Taieb, D., Beuschlein, F., Fassnacht, M., Kroiss, M., Eisenhofer, G., Grossman, A., & Pacak, K. (2022) · Endocrine Reviews · doi:10.1210/endrev/bnab019 · Cited by 417
Adrenal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Berruti, A., Baudin, E., Gelderblom, H., Haak, H. R., Porpiglia, F., Fassnacht, M., & Pentheroudakis, G. (2012) · Annals of Oncology · doi:10.1093/annonc/mds231 · Cited by 331
New Perspectives on Pheochromocytoma and Paraganglioma: Toward a Molecular Classification
Crona, J., Taïeb, D., & Pacak, K. (2017) · Endocrine Reviews · doi:10.1210/er.2017-00062 · Cited by 324
Current and Future Treatments for Malignant Pheochromocytoma and Sympathetic Paraganglioma
Jimenez, C., Rohren, E., Habra, M. A., Rich, T., Jimenez, P., Ayala-Ramirez, M., & Baudin, E. (2013) · Current Oncology Reports · doi:10.1007/s11912-013-0320-x · Cited by 178
[131I]Iodometomidate for targeted radionuclide therapy of advanced adrenocortical carcinoma
Hahner, S., Kreissl, M. C., Fassnacht, M., Haenscheid, H., Knoedler, P., Lang, K., Buck, A. K., Reiners, C., Allolio, B., & Schirbel, A. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-2765 · Cited by 87
“myelodysplastic syndrome) cannot be excluded as has been described in few patients treated with high-dose [(131)I]metaiodobenzylguanidine for metastatic pheochromocytoma and paraganglioma (32).”
Background
Metadata
- Authors
- Gonias, S., Goldsby, R., Matthay, K. K., Hawkins, R., Price, D., Huberty, J., Damon, L., Linker, C., Sznewajs, A., Shiboski, S., & Fitzgerald, P.
- Venue
- Journal of Clinical Oncology
- Published
- 2009-09-01
- Volume
- 27
- Issue
- 25
- Pages
- 4162-4168
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2167466716
- Cited by
- 245
- References
- 13
- FWCI
- 11.07
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.